BioSpace News Archive

Amarin Corporation plc today announced that new data that add to the growing body of knowledge on VASCEPA®/VAZKEPA (icosapent ethyl) in patients at risk for major adverse cardiovascular events will be presented at ESC Congress 2021, organized by the European Society of Cardiology (ESC), being held virtually from August 27 – August 30, 2021.

Teligent, Inc., a New Jersey-based generics pharmaceutical company, announced its financial results for the second quarter of 2021 and provided a business update.

Eko, a cardiopulmonary digital health company, announced the launch of the next generation Eko DUO.

Travere Therapeutics, Inc. today announced positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan, an investigational product candidate for the treatment of IgA nephropathy (IgAN).

Centessa Pharmaceuticals plc today reported financial results for the quarter ended June 30, 2021, and provided a review of recent accomplishments and anticipated upcoming milestones.

Biosight Ltd . today announced the initiation of a Phase 2 trial to evaluate aspacytarabine (BST-236), Biosight’s proprietary antimetabolite, as a second line treatment for patients with relapsed or refractory myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

Gracell Biotechnologies Inc. today announced an exclusive license agreement with FutureGen Biopharm (“FutureGen”), an innovative biopharmaceutical company, to develop engineered immune cell therapies targeting Claudin 18.2 (“CLDN18.2") in solid tumors.

Viracta Therapeutics, Inc. today announced the appointments of Flavia Borellini , Ph.D., and Jane F. Barlow , M.D., MPH, MBA, as independent members to Viracta’s Board of Directors.

Fresenius Medical Care North America and Cigna announce an expansion of their national effort to improve health outcomes and lower the cost of care for people living with kidney failure, or end stage renal disease.

Masimo announced the findings of a study published in the Journal of Pain & Relief in which Dr. Jacques Chelly and colleagues at the University of Pittsburgh investigated the utility of Masimo Bridge®, an auricular field nerve stimulator, in reducing postoperative opioid requirements in patients undergoing kidney donor surgery.